Health Canada’s consultation on new health-related labelling for tobacco products
https://policybase.cma.ca/link/policy13939

POLICY TYPE
Response to consultation

DATE
2018-12-14

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Implementation of National Pharmacare

https://policybase.cma.ca/link/policy13933

POLICY TYPE Response to consultation
DATE 2018-10-02
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE
Response to consultation

DATE
2018-09-06

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear Mr. Komor,

The Canadian Medical Association (CMA) appreciates the opportunity to participate in the public consultation on proposed front-of-package (FOP) labelling for pharmaceuticals, in particular cannabis and other drugs.

The CMA supports the inclusion of information such as the generic or brand name and active ingredients on the FOP, as well as the use-by date, instructions for use, and any warnings or contraindications. This information is crucial for consumers to make informed decisions about their health and well-being. However, the CMA has concerns about the potential for FOP labelling to be overly technical and confusing for consumers, particularly those who may not have a medical background.

The CMA recommends that the FOP label include a statement confirming the dosage strength and informing consumers of the potential for misuse, as part of the proposed message. This approach would help ensure that consumers understand the importance of following the recommended dosage and the potential consequences of misuse.

The CMA supports the development of a user-friendly approach to FOP labelling, ensuring that the information is presented in a way that is accessible to all consumers. This approach could include the use of clear, concise language and the avoidance of technical jargon.

Yours sincerely,

[Signature]

[Name]

Canadian Medical Association

---

The CMA has supported recommendations to include information on the FOP about the potential for misuse, as part of the proposed message. This approach would help ensure that consumers understand the importance of following the recommended dosage and the potential consequences of misuse.

The CMA supports the development of a user-friendly approach to FOP labelling, ensuring that the information is presented in a way that is accessible to all consumers. This approach could include the use of clear, concise language and the avoidance of technical jargon.

Yours sincerely,

[Signature]

[Name]

Canadian Medical Association

[Note: The text above is an example and does not reflect the actual content of the policy.]
Health and health care for an aging population
https://policybase.cma.ca/link/policy11061

POLICY TYPE: Policy document
LAST REVIEWED: 2018-03-03
DATE: 2013-12-07
REPLACES: PD00-03 - Principles for medical care of older persons
TOPICS: Health care and patient safety
Health systems, system funding and performance

Documents

Health and Health Care for an Aging Population

Policy Summary of
The Canadian Medical Association
December 2013
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

**POLICY TYPE**
Parliamentary submission

**DATE**
2018-02-15

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents